Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: A pilot study

Psychiatry Research - Neuroimaging

Volumn 146, Issue 2, 2006, Pages 149-155

  Mathews, Jose ^a   Garcia, Keith S ^a   Mintun, Mark A ^a   Sheline, Yvette I ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT2A receptors; Antidepressants; Neuroimaging; Positron emission tomography

Indexed keywords

ANTIDEPRESSANT AGENT; OLANZAPINE; SEROTONIN 2A RECEPTOR;

ADULT; AGED; AGITATION; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; COORDINATION DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HAMILTON SCALE; HUMAN; INFORMATION PROCESSING; MAJOR DEPRESSION; MALE; MENTAL CONCENTRATION; MONOTHERAPY; MYALGIA; NAUSEA; NEUROIMAGING; OPEN STUDY; PHARYNGITIS; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; SIDE EFFECT; SOMNOLENCE; SWEATING; TIME SERIES ANALYSIS; TREMOR; VISUAL DISORDER; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; BENZODIAZEPINES; BRAIN; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RECEPTOR, SEROTONIN, 5-HT2A; SEVERITY OF ILLNESS INDEX;

EID: 33646490701     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2005.08.003     Document Type: Article

References (27)

1. Arango V., Underwood M.D., and Mann J.J. Alterations in monoamine receptors in the brain of suicide victims. Journal of Clinical Psychopharmacology 12 Supplement 2 (1992) 8S-12S
2. Bogenschutz M.P., and Nurnberg G.H. Olanzapine versus placebo in the treatment of borderline personality disorder. Journal of Clinical Psychiatry 65 (2004) 104-109
3. Brannan S.K., Mallinckrodt C.H., Detke M.J., Watkin J.G., and Tollefson G.D. Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies. Journal of Psychiatric Research 39 2 (2005) 161-172 (Mar)
4. 2-selective adrenoceptor antagonist Org 3770 (mirtazapine, Remeron®) enhances noradrenergic and serotonergic transmission. Human Psychopharmacology 10 (1995) S107-S118
5. Detke M.J., Wiltse C.G., Mallinckrodt C.H., McNamara R.K., Demitrack M.A., and Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. European Neuropsychopharmacology 14 6 (2004) 457-470 (Dec)
6. Fiorella D., Rabin R.A., and Winter J.C. The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine. Psychopharmacology 119 2 (1995) 222-230
7. Ghaemi S.N., Cherry E.L., Katzow J.A., and Goodwin F.K. Does olanzapine have antidepressant properties? A retrospective preliminary study. Bipolar Disorder 2 (2000) 196-199
8. Guy, W., 1976. ECDEU Assessment Manual for Psychopharmacology. Revised, Publication ADM 76-338. US Department of Health Education and Welfare, Bethesda MD.
9. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23 (1960) 56-62
10. Keck P.E., Strakowski S.M., and McElroy S.L. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. Journal of Clinical Psychiatry 61 (2000) 4-9
11. Lemaire C., Cantineau R., Guillaume M., Plenevaux A., and Christiaens L. Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. Journal of Nuclear Medicine 32 12 (1991) 2266-2272
12. Maier W., and Philipp M. Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale. Pharmacopsychiatry 18 (1985) 114-115
13. 2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. Archives of General Psychiatry 43 (1986) 954-959
14. Meyer J.H., Cho R., Kennedy S., and Kapur S. The effects of single dose nefazodone and paroxetine upon 5-HT2A binding potential in humans using [18F]-setoperone PET. Psychopharmacology 144 3 (1999) 279-281
15. Mintun M.A., Sheline Y.I., Moerlein S.M., Vlassenko A.G., Huang Y., and Snyder A.Z. Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography. Biological Psychiatry 55 (2004) 217-224
16. Nelson E.B., Rielage E., Welge J.A., and Keck P.E. An open trial of olanzapine in the treatment of patients with psychotic depression. Annals of Clinical Psychiatry 13 (2001) 147-151
17. Overall J.E., and Gorham D.R. The Brief Psychiatric Rating Scale. Psychological Reports 10 (1962) 799-812
18. Parker G. Olanzapine augmentation in the treatment of melancholia: the trajectory of improvement in rapid responders. International Clinical Psychopharmacology 17 (2002) 87-89
19. 2A receptor antagonist, EMD 281014, significantly increases swimming and decreases immobility in male congenital learned helpless rats in the forced swim test. Synapse 52 (2004) 73-75
20. Schatzberg A.F. New approaches to managing psychotic depression. Journal of Clinical Psychiatry 64 (2003) 19-23
21. Schooler N.R., and Kane J.M. Research diagnoses for tardive dyskinesia. Archives of General Psychiatry 39 (1982) 486-487
22. Schulz S.C., Camlin K.L., Berry S.A., and Jesberger J.A. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biological Psychiatry 46 (1999) 1429-1435
23. 2A receptors in midlife than in late life. American Journal of Psychiatry 159 (2002) 430-435
24. Shelton R.C., Tollefson G.D., Tohen M., Stahl S., Gannon K.S., Jacobs T.G., Buras W.R., Bymaster F.P., Zhang W., Spencer K.A., Feldman P.D., and Meltzer H.Y. A novel augmentation strategy for treating resistant major depression. American Journal of Psychiatry 158 (2001) 155-156
25. Simpson G.M., and Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica. Supplementum 212 (1970) S11-S19
26. Tohen M., Vieta E., Calabrese J., Ketter T.A., Sachs G., Bowden C., Mitchell P.B., Centorrino F., Risser R., Baker R.W., Evans A.R., Beymer K., Dube S., Tollefson G.D., and Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Archives of General Psychiatry 60 (2003) 1079-1088
27. Zhang W., and Bymaster F.P. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology 141 3 (1999) 267-278